Weekly Top News – IBD – September 14, 2020

September 14, 2020

etrolizumab (RG7413) / Roche
A Study of Etrolizumab-Based Induction Therapy Combinations Followed by Etrolizumab Maintenance Therapy in Patients with Moderate-To-Severe Ulcerative Colitis (clinicaltrialsregister.eu) – Sep 12, 2020 – P3; N=372; Ongoing; Sponsor: F. Hoffmann-La Roche Ltd

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn’s Disease Who Failed Prior Biologic Treatment (clinicaltrials.gov) – Sep 11, 2020 – P3; N=618; Active, not recruiting; Sponsor: AbbVie; Recruiting –> Active, not recruiting

No Comments

Post a Comment